Preclinical News and Research

RSS

Study reveals that color vision abnormalities increase with age

Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Feb 2014

Antibody in people with MS may be present long before onset of symptoms

An antibody found in the blood of people with multiple sclerosis (MS) may be present long before the onset of the disease and its symptoms, according to a study released today that will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

24 Feb 2014

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.

21 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Jubilant Biosys expands drug discovery alliance with Janssen Pharmaceutica

Jubilant Biosys, a Bengaluru based subsidiary of Jubilant Life Sciences, announced today that it has expanded its drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium.

20 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that the Food and Drug Administration has granted Fast Track designation to the GFT505 development program in NASH, with effect from February 14, 2014.

18 Feb 2014

Researchers conduct pioneering translational study on immediate antidepressant effect of DBS

A team of UCA researchers led by Professor Esther Berrocoso and in joint collaboration with the mental health research groups of the Centro de Investigación Biomédica en Red de Salud Mental have carried out a pioneering project in Spain.

17 Feb 2014

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a supply and distribution agreement with Sirion Biotech GmbH.

17 Feb 2014

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has awarded Soligenix a Small Business Innovation Research grant to support further preclinical development of SGX943 as a treatment for melioidosis.

14 Feb 2014

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

More than 30 European universities and companies, led by GlaxoSmithKline, are joining forces in a six-year programme funded by the Innovative Medicines Initiative (IMI) for the sum of EUR 85 millions with the aim of developing new antibiotics against Gram-negative pathogens.

14 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Agenus closes previously announced acquisition of 4-Antibody

Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

13 Feb 2014

Researchers identify effective target for human autoimmune disease

Researchers at King's College London have identified a new gene (PIM1), which could be an effective target for innovative treatments and therapies for the human autoimmune disease, psoriasis.

13 Feb 2014

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

13 Feb 2014

Tamoxifen drug appears to kill fungus associated with deadly brain infection

The drug tamoxifen appears to kill a fungus associated with a deadly brain infection that afflicts HIV/AIDS patients, according to a University of Rochester study published online today by mBio, the journal of the American Society for Microbiology.

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Researchers introduce unique micro-robotic technique for tissue engineering and 3D printing

Researchers at Brigham and Women's Hospital and Carnegie Mellon University have introduced a unique micro-robotic technique to assemble the components of complex materials, the foundation of tissue engineering and 3D printing.

11 Feb 2014

Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

The University of Pittsburgh's Center for Medical Innovation (CMI) awarded a total of $82,000 to six research groups through its 2013 Round-2 Pilot Funding Program for Early Stage Medical Technology Research and Development.

11 Feb 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Preclinical News and Research

Study reveals that color vision abnormalities increase with age

Antibody in people with MS may be present long before onset of symptoms

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Jubilant Biosys expands drug discovery alliance with Janssen Pharmaceutica

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

Researchers conduct pioneering translational study on immediate antidepressant effect of DBS

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Agenus closes previously announced acquisition of 4-Antibody

Researchers identify effective target for human autoimmune disease

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

Tamoxifen drug appears to kill fungus associated with deadly brain infection

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Researchers introduce unique micro-robotic technique for tissue engineering and 3D printing

Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics